表紙
市場調査レポート

ウェット型(新生血管型/滲出型)黄斑変性症:パイプライン分析

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245984
出版日 ページ情報 英文 267 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
ウェット型(新生血管型/滲出型)黄斑変性症:パイプライン分析 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 267 Pages
概要

ウェット型(新生血管型/滲出型)黄斑変性症は、失明をもたらす慢性の眼疾患です。症状は、視覚の歪み、色の強さや明るさの低下、視界の中にぼける部分・欠ける部分がある、突発性が挙げられます。素因として、年齢、喫煙、肥満、高血圧、炎症、心血管疾患などが挙げられます。

当レポートでは、ウェット型(新生血管型/滲出型)黄斑変性症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ウェット型(新生血管型/滲出型)黄斑変性症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Aciont Inc.
  • Allergan Plc
  • Amakem NV
  • Apellis Pharmaceuticals, Inc.
  • Apexigen, Inc.
  • Applied Genetic Technologies Corporation
  • Avalanche Biotechnologies, Inc.
  • Benitec Biopharma Limited
  • BIOCAD
  • Boehringer Ingelheim GmbH
  • Charlesson LLC.
  • Chong Kun Dang Pharmaceutical Corp.
  • Circadian Technologies Limited
  • Clanotech AB
  • Clearside BioMedical, Inc.
  • Coherus BioSciences, Inc.
  • 第一三共
  • Delenex Therapeutics AG
  • Eleven Biotherapeutics Inc.
  • Exonate Limited
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • GTx, Inc.
  • iCo Therapeutics Inc.
  • Icon Bioscience, Inc.
  • Kala Pharmaceuticals, Inc.
  • Kodiak Sciences, Inc.
  • Mabion SA
  • Mitotech S.A.
  • Neurotech Pharmaceuticals, Inc.
  • Ocular Therapeutix, Inc.
  • Ohr Pharmaceutical Inc.
  • Ophthotech Corp.
  • Oxford BioMedica Plc
  • PanOptica, Inc.
  • Pfenex Inc.
  • Pfizer Inc.
  • pSivida Corp.
  • Quark Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.
  • RXi Pharmaceuticals Corporation
  • 参天製薬
  • 三和化学研究所
  • TRACON Pharmaceuticals, Inc.
  • TWi Pharmaceuticals, Inc.
  • Tyrogenex, Inc.
  • Xbrane Biopharma AB

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (アフリベルセプト + nesvacumab)
  • (アフリベルセプト + rinucumab)
  • abicipar pegol
  • AC-301
  • ACX-107
  • アフリベルセプト
  • アフリベルセプトのバイオシミラー
  • AGN-151200
  • ALG-1001
  • AMA-0428
  • APL-2
  • APX-003
  • APX-3330
  • AVA-101
  • AVA-201
  • avacincaptad pegol sodium
  • AXT-108
  • bertilimumab
  • Beta-LGND2
  • ベバシズマブのバイオシミラー
  • BI-144807
  • brolucizumab
  • C-16Y
  • CLT-005
  • CLT-28643
  • cyclosporine
  • DE-120
  • DLX-1008
  • DNX-214
  • Doxarubicin Pegylated
  • 加齢性黄斑変性症(AMD)治療薬
  • ウェット型 AMD・ドライ型 AMD 治療薬
  • DS-7080
  • ENV-1305
  • ENV-705
  • GB-101
  • GB-102
  • ウェット型AMD 向け遺伝子療法
  • K-106
  • KSI-201
  • LHA-510
  • LMG-324
  • ウェット型AMD 向け VEGF 阻害モノクローナル抗体
  • nesvacumab
  • NT-503
  • NT-506
  • OCU-200
  • OLX-301
  • ONL-1204
  • OXB-201
  • PAN-90806
  • pegpleranib sodium
  • PF-05206388
  • PF-655
  • plastoquinone decyl triphenylphosphonium bromide
  • ウェット型AMD 向け VEGF阻害タンパク質
  • ラニビズマブ
  • ラニビズマブのバイオシミラー
  • 加齢性黄斑変性症向け組換型タンパク質
  • ウェット型AMD 向け VEGF 阻害組換型タンパク質
  • RG-7716
  • RGX-314
  • RXI-109
  • SK-1011
  • ウェット/ドライ型 AMD向け小分子
  • ウェット型AMD 向け VEGF/PDGF阻害小分子
  • SPHINX-31
  • squalamine lactate
  • ウェット型AMD向け VEGF阻害合成ペプチド
  • TRC-105
  • トリアムシノロン・アセトニド
  • TT-211
  • TT-231
  • VGX-300
  • X-82

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8376IDB

Summary

Global Markets Direct's, 'Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016', provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
  • The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
  • The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 8
  • Introduction 9
  • Global Markets Direct Report Coverage 9
  • Wet (Neovascular / Exudative) Macular Degeneration Overview 10
  • Therapeutics Development 11
  • Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11
  • Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16
  • Late Stage Products 16
  • Clinical Stage Products 17
  • Early Stage Products 18
  • Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19
  • Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 25
  • Aciont Inc. 25
  • Adverum Biotechnologies, Inc. 26
  • Allergan Plc 27
  • Alteogen Inc. 28
  • Amakem NV 29
  • Ampio Pharmaceuticals, Inc. 30
  • Apellis Pharmaceuticals, Inc. 31
  • Apexigen, Inc. 32
  • Applied Genetic Technologies Corporation 33
  • Benitec Biopharma Limited 34
  • Boehringer Ingelheim GmbH 35
  • Cell Medica Limited 36
  • Charlesson LLC. 37
  • Cipla Ltd. 38
  • Clanotech AB 39
  • Clearside BioMedical, Inc. 40
  • Clonz Biotech Private Limited 41
  • Coherus BioSciences, Inc. 42
  • Daiichi Sankyo Company, Limited 43
  • Diffusion Pharmaceuticals Inc. 44
  • Eleven Biotherapeutics Inc. 45
  • Exonate Limited 46
  • F. Hoffmann-La Roche Ltd. 47
  • Formycon AG 48
  • Graybug Vision Inc 49
  • GTx, Inc. 50
  • iCo Therapeutics Inc. 51
  • Icon Bioscience, Inc. 52
  • Iconic Therapeutics, Inc. 53
  • Kala Pharmaceuticals, Inc. 54
  • Kodiak Sciences Inc. 55
  • Mabion SA 56
  • MeiraGTx Limited 57
  • Mitotech S.A. 58
  • Ocular Therapeutix, Inc. 59
  • Ohr Pharmaceutical Inc. 60
  • Ophthotech Corp. 61
  • Oxford BioMedica Plc 62
  • PanOptica, Inc. 63
  • Pfenex Inc. 64
  • Pfizer Inc. 65
  • pSivida Corp. 66
  • Regeneron Pharmaceuticals Inc 67
  • RegenxBio Inc. 68
  • RXi Pharmaceuticals Corporation 69
  • Santen Pharmaceutical Co., Ltd. 70
  • Sanwa Kagaku Kenkyusho Co., Ltd. 71
  • TRACON Pharmaceuticals, Inc. 72
  • TWi Pharmaceuticals, Inc. 73
  • Tyrogenex, Inc. 74
  • Xbrane Biopharma AB 75
  • Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 76
  • Assessment by Monotherapy Products 76
  • Assessment by Combination Products 77
  • Assessment by Target 78
  • Assessment by Mechanism of Action 81
  • Assessment by Route of Administration 85
  • Assessment by Molecule Type 87
  • Drug Profiles 89
  • (aflibercept + nesvacumab) - Drug Profile 89
  • (aflibercept + rinucumab) - Drug Profile 90
  • A-006 - Drug Profile 91
  • abicipar pegol - Drug Profile 92
  • AC-301 - Drug Profile 95
  • ACX-107 - Drug Profile 96
  • aflibercept - Drug Profile 97
  • aflibercept biosimilar - Drug Profile 106
  • aflibercept biosimilar - Drug Profile 107
  • AGN-151200 - Drug Profile 108
  • ALG-1001 - Drug Profile 110
  • AMA-0428 - Drug Profile 113
  • APL-2 - Drug Profile 114
  • APX-003 - Drug Profile 116
  • APX-3330 - Drug Profile 117
  • AVA-101 - Drug Profile 119
  • AVA-201 - Drug Profile 122
  • avacincaptad pegol sodium - Drug Profile 123
  • axitinib - Drug Profile 125
  • AXT-108 - Drug Profile 127
  • bertilimumab - Drug Profile 128
  • Beta-LGND2 - Drug Profile 132
  • BI-144807 - Drug Profile 134
  • brolucizumab - Drug Profile 135
  • C-16Y - Drug Profile 137
  • CBT-128 - Drug Profile 138
  • CLT-005 - Drug Profile 139
  • CLT-28643 - Drug Profile 140
  • cyclosporine - Drug Profile 141
  • DA-3131 - Drug Profile 142
  • danazol - Drug Profile 143
  • DE-120 - Drug Profile 147
  • DNX-214 - Drug Profile 148
  • Doxarubicin Pegylated - Drug Profile 149
  • Drug for Age Related Macular Degeneration - Drug Profile 150
  • DS-7080 - Drug Profile 151
  • ENV-1305 - Drug Profile 152
  • GB-101 - Drug Profile 153
  • Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile 154
  • Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 155
  • hI-con1 - Drug Profile 156
  • IVMED-50 - Drug Profile 158
  • IVMED-55 - Drug Profile 159
  • K-106 - Drug Profile 160
  • KSI-201 - Drug Profile 161
  • LHA-510 - Drug Profile 162
  • Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 163
  • OCU-200 - Drug Profile 164
  • OLX-301 - Drug Profile 165
  • ONL-1204 - Drug Profile 166
  • OPT-302 - Drug Profile 167
  • OXB-201 - Drug Profile 171
  • PAN-90806 - Drug Profile 173
  • pegpleranib sodium - Drug Profile 175
  • PF-05206388 - Drug Profile 178
  • PF-655 - Drug Profile 180
  • plastoquinone decyl triphenylphosphonium bromide - Drug Profile 182
  • Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 184
  • ranibizumab - Drug Profile 185
  • ranibizumab biosimilar - Drug Profile 191
  • ranibizumab biosimilar - Drug Profile 192
  • ranibizumab biosimilar - Drug Profile 193
  • ranibizumab biosimilar - Drug Profile 195
  • ranibizumab biosimilar - Drug Profile 196
  • ranibizumab biosimilar - Drug Profile 197
  • ranibizumab biosimilar - Drug Profile 198
  • Recombinant Protein for Age Related Macular Degeneration - Drug Profile 199
  • Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 200
  • RES-529 - Drug Profile 201
  • RG-7716 - Drug Profile 205
  • RGX-314 - Drug Profile 206
  • RXI-109 - Drug Profile 208
  • SK-1011 - Drug Profile 214
  • Small Molecule for Wet AMD and Dry AMD - Drug Profile 215
  • Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 216
  • Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile 217
  • SPHINX-31 - Drug Profile 218
  • squalamine lactate - Drug Profile 219
  • sunitinib malate - Drug Profile 227
  • Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 229
  • TRC-105 - Drug Profile 230
  • triamcinolone acetonide - Drug Profile 238
  • TT-211 - Drug Profile 239
  • TT-231 - Drug Profile 240
  • X-82 - Drug Profile 241
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 244
  • Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 248
  • Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 249
  • Featured News & Press Releases 249
  • Appendix 259
  • Methodology 259
  • Coverage 259
  • Secondary Research 259
  • Primary Research 259
  • Expert Panel Validation 259
  • Contact Us 259
  • Disclaimer 260

List of Tables

  • Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18
  • Number of Products under Development by Companies, H2 2016 19
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 20
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 21
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 22
  • Comparative Analysis by Late Stage Development, H2 2016 23
  • Comparative Analysis by Clinical Stage Development, H2 2016 24
  • Comparative Analysis by Early Stage Development, H2 2016 25
  • Products under Development by Companies, H2 2016 26
  • Products under Development by Companies, H2 2016 (Contd..1) 27
  • Products under Development by Companies, H2 2016 (Contd..2) 28
  • Products under Development by Companies, H2 2016 (Contd..3) 29
  • Products under Development by Companies, H2 2016 (Contd..4) 30
  • Products under Development by Companies, H2 2016 (Contd..5) 31
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2016 32
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H2 2016 33
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2016 34
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alteogen Inc., H2 2016 35
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2016 36
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 37
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2016 38
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2016 39
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2016 40
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016 41
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016 42
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cell Medica Limited, H2 2016 43
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016 44
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cipla Ltd., H2 2016 45
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2016 46
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2016 47
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H2 2016 48
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H2 2016 49
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 50
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 51
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016 52
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2016 53
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 54
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2016 55
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016 56
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2016 57
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016 58
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016 59
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2016 60
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 61
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016 62
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2016 63
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016 64
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2016 65
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2016 66
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2016 67
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016 68
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016 69
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2016 70
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2016 71
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2016 72
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2016 73
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 74
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2016 75
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 76
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 77
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 78
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 79
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 80
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2016 81
  • Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016 82
  • Assessment by Monotherapy Products, H2 2016 83
  • Assessment by Combination Products, H2 2016 84
  • Number of Products by Stage and Target, H2 2016 86
  • Number of Products by Stage and Mechanism of Action, H2 2016 89
  • Number of Products by Stage and Route of Administration, H2 2016 93
  • Number of Products by Stage and Molecule Type, H2 2016 95
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2016 251
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2016 252
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2016 253
  • Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..3), H2 2016 254
  • Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2016 255

List of Figures

  • Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18
  • Number of Products under Development by Companies, H2 2016 19
  • Comparative Analysis by Late Stage Development, H2 2016 23
  • Comparative Analysis by Clinical Stage Development, H2 2016 24
  • Comparative Analysis by Early Stage Products, H2 2016 25
  • Assessment by Monotherapy Products, H2 2016 83
  • Number of Products by Top 10 Targets, H2 2016 85
  • Number of Products by Stage and Top 10 Targets, H2 2016 85
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 88
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 88
  • Number of Products by Top 10 Routes of Administration, H2 2016 92
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016 92
  • Number of Products by Top 10 Molecule Types, H2 2016 94
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 94
Back to Top